Impfprävention HPV-assoziierter Neoplasien

G. Gross; N. Becker; N. H. Brockmeyer; S. Esser; U. Freitag; M. Gebhardt; L. Gissmann; P. Hillemanns; H. Grundhewer; H. Ikenberg; H. Jessen; A. Kaufmann; S. Klug; J. P. Klussmann; A. Nast; D. Pathirana; K. U. Petry; H. Pfister; U. Röllinghof; P. Schneede; A. Schneider; E. Selka; S. Singer; S. Smola; B. Sporbeck; M. von Knebel Doeberitz; P. Wutzler

doi:10.1055/s-0034-1382013

Laryngo-Rhino-Otologie, Table of Contents

Laryngorhinootologie 2014; 93(12): 848-856
DOI: 10.1055/s-0034-1382013

Leitlinie

Impfprävention HPV-assoziierter Neoplasien

Empfehlungen aus der aktuellen S3-Leitlinie des HPV-Management-Forums der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. – AWMF Leitlinien-Register Nr. 082-002 (Kurzfassung), gültig bis 31.12.2018Vaccination against HPV-Associated NeoplasiasRecommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society – AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31^st, 2018

Authors

G. Gross

¹Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin, Universität Rostock, Rostock
N. Becker

²Deutsches Krebsforschungszentrum (DKFZ), Epidemiologie von Krebserkrankungen (C020), Heidelberg
N. H. Brockmeyer

³Klinik für Dermatologie und Allergologie der Ruhr-Universität, Bochum
S. Esser

⁴Klinik für Dermatologie und Venerologie, Universitätsklinikum Essen, Essen
U. Freitag

⁵Frauenarztpraxis, Wismar
M. Gebhardt

⁶Frauenselbsthilfe nach Krebs, Forchheim
L. Gissmann

⁷Deutsches Krebsforschungszentrum (DKFZ), FS Infektion und Krebs, Heidelberg
P. Hillemanns

⁸Medizinische Hochschule Hannover (MHH), Frauenklinik, Abt. I für Frauenheilkunde und Geburtshilfe, Hannover
H. Grundhewer

⁹Ausschuss Prävention des Berufsverbandes der Kinder- und Jugendärzte (BVKJ), Berlin
H. Ikenberg

¹⁰MVZ für Zytologie und Molekularbiologie (CytoMol), Frankfurt/M.
H. Jessen

¹¹Praxis Jessen + Kollegen, Berlin
A. Kaufmann

¹²Gynäkologische Tumorimmunologie, Gynäkologie mit Hochschulambulanz, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
S. Klug

¹³Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden
J. P. Klussmann

¹⁴Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Klinikum der Universität Gießen, Gießen
A. Nast

¹⁵Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
D. Pathirana

¹⁵Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
K. U. Petry

¹⁶Klinikum Wolfsburg, Abteilung Gynäkologische Onkologie, Wolfsburg
H. Pfister

¹⁷Institut für Virologie der Universität zu Köln
U. Röllinghof

¹⁸VulvaKarzinom-SHG e. V., Wilhelmshaven
P. Schneede

¹⁹Klinikum Memmingen, Klinik für Urologie, Memmingen
A. Schneider

²⁰Klinik und Poliklinik für Gynäkologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
E. Selka

¹⁸VulvaKarzinom-SHG e. V., Wilhelmshaven
S. Singer

²¹Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Institut für Medizinische Biometrie, Epidemiologie und Informatik, Abt. Epidemiologie und Versorgungsforschung, Mainz
S. Smola

²²Institut für Virologie, Institut für Infektionsmedizin, Universität des Saarlandes, Homburg/Saar
B. Sporbeck

¹⁵Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
M. von Knebel Doeberitz

²³Abteilung für Molekulare Pathologie, Pathologisches Institut des Universitätsklinikum Heidelberg, Heidelberg
P. Wutzler

²⁴Universitätsklinikum Jena (Friedrich-Schiller-Universität), Institut für Virologie und Antivirale Therapie, Beutenberg Campus, Jena

Abstract

Full Text

References

Literatur
1 Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N et al. European guidelines for quality assurance in cervical cancer screening. 2^nd revised ed. Bertrams 2008. ISBN 978-92-79-07698-5
2 Jahn I, Eberle A, Niehues C, Birn A, Horch K. Gesundheitsberichterstattung des Bundes, Gebärmuttererkrankungen. Heft 37. Robert Koch-Institut 2007;
3 Gross G, Tyring SK. (eds.). Sexually transmitted Infections and sexually transmitted Diseases. Springer; 2011. ISBN 978-3-642-14662-6
4 Pathirana D, Hillemanns P, Petry KU, Becker N, Brockmeyer NH, Erdmann R et al. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia. Vaccine 2009; 27: 4551-4559
5 Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204
6 Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F et al. A review of human carcinogens – Part B: biological agents. Lancet Oncol 2009; 10: 321-322
7 Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011; 121: 4593-4599
8 Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907
9 Robert Koch-Institut Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren – Empfehlung und Begründung. Epidemiologisches Bulletin 2007: 12
10 Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765
11 Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278
12 Esposito S, Birlutiu V, Jarcuska P, Perino A, Man SC, Vladareanu R et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Ped Inf Dis J 2011; 30: e49-e55
13 Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, Tang Y et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011; 305: 1424-1431
14 Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. Journal of Womenʼs Health (Larchmont) 2010; 19: 1441-1447
15 Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. Br Med J 2012; 344: e1401
16 Garland S. on behalf of the HPV PATRICIA Study Group. Does the HPV‑16/ 18 AS04-adjuvanted vaccine benefit women with cervical disease?. EUROGIN 2011 2011; Lissabon
17 European Medicines Agency Cervarix. 2012 Online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124&-murl=menus/medicines/medicines.jsp
18 Naud P, Roteli-Martins CM, De Carvalho N, Teixeira J, Borba P, Sanchez N et al. HPV‑16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years. Berlin: 27^th International papillomavirus conference and clinical workshop; 2011. Online: http://www.hpv2011.org/pics/1/4/Abstract%20Book%202%20APSC%20WEBB%20110922.pdf
19 GlaxoSmithKline Fachinformation Cervarix 2007 Online: http://www.fachinfo.de/data/fi/jsearch?praep
20 Sanofi Pasteur MSD. Fachinformation Gardasil. 2007 Online: http://www.fachinfo.de/data/fi/jsearch?praep
21 FUTURE II Study Group . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927
22 Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001; 19: 1783-1793
23 Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255
24 Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Human Vaccines 2007; 3: 109-115
25 Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007; 369: 2161-2170
26 De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a metaanalysis. Int J Cancer 2009; 124: 1626-1636
27 Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transplant International: Official Journal of the European Society for Organ Transplantation 2004; 17: 366-369
28 Wieland U, Stuecker M, Kreuter A. HPV vaccine against anal intraepithelial neoplasia. N Engl J Med 2012; 366: 378 author reply − 9
29 Busnach G, Piselli P, Arbustini E, Baccarani U, Burra P, Carrieri MP et al. Immunosuppression and cancer: a comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transpl Proc 2006; 38: 3533-3535
30 Giuliano AR, Palefsky JM, Goldstone S, Moreira jr ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364: 401-411
31 Palefsky JM, Giuliano AR, Goldstone S, Moreira jr ED, Aranda C, Jessen H et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-1585
32 Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003; 89: 1248-1254
33 Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011; 120: 430-438
34 Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007; 13: 2599-2605
35 Quigley NB, Potter NT, Chivukula M, Knight MZ, Welch JR, Olson MC. Rate of detection of high-risk HPV with two assays inwomen ≥= 30 years of age. J Clin Virol 2011; 52: 23-27
36 Bohmer G, van den Brule AJ, Brummer O, Meijer CL, Petry KU. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 2003; 189: 118-120
37 Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 1-6
38 Ikenberg H. Detection of HPV DNA and RNA. In: Pfister H. (ed.). Monographs in Virology: Prophylaxis and early Detection of HPV-related Neoplasia. Basel: Karger; 2011: 109-119
39 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) Arbeitsgemeinschaft Infektiologie und Infektimmunologie in Gynäkologie und Geburtshilfe (AGII); Berufsverband der Frauenärzte (BVF); Deutsche Gesellschaft für Pathologie (DGP); Deutsche Gesellschaft für Urologie (DGU); Deutsche Krebsgesellschaft (DKG) et al. S2 k Leitlinie zur Prävention, Diagnostik und Therapie der HPV-Infektion und präinvasiver Läsionen des weiblichen Genitale. 2010. Online: http://www.dggg.de/fileadmin/public_docs/Leitlinien/1-4-4-hpv-2010.pdf
40 European Medicines Agency Gardasil. 2012 Online: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp
41 Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29: 8279-8284
42 Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 750-757
43 Pomfret TC, Gagnon JM, Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther 2011; 36: 1-9
44 Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011; 11: 13
45 Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Int Med 2012; 271: 193-203
46 Della Corte C, Carlucci A, Francalanci P, Alisi A, Nobili V. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011; 29: 4654-4656
47 Ojaimi S, Buttery JP, Korman TM. Quadrivalent human papillomavirus recombinant vaccine associated lipoatrophy. Vaccine 2009; 27: 4876-4878
48 Katoulis AC, Liakou A, Bozi E, Theodorakis M, Alevizou A, Zafeiraki A et al. Erythema multiforme following vaccination for human papillomavirus. Dermatology 2010; 220: 60-62
49 Perez-Carmona L, Aguayo-Leiva I, Gonzalez-Garcia C, Jaen-Olasolo P. The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration. Dermatology 2010; 221: 197-200
50 Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H et al. Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006–2009. Vaccine 2011; 29: 886-889
51 Alvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, del Real-Francia MA, Gallardo-Alcaniz MJ, Lopez-Gomez JL. Trastornos neurologicos desmielinizantes y vacunacion del papilomavirus humano [Demyelinating disease and vaccination of the human papillomavirus]. Revista de Neurologia 2011; 52: 472-476
52 Bomprezzi R, Wildemann B. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2010; 74: 864-865
53 Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry 2011; 82: 1296-1298
54 DiMario FJ, Hajjar M, Ciesielski T. A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol 2010; 25: 321-327
55 Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2009; 72: 2132-2133
56 Mentzer D, Keller-Stanislawski B. Daten zur Pharmakovigilanz von Impfstoffen aus dem Jahr 2010. Bulletin zur Arzneimittelsicherheit. 2012: 21-29
57 Erlewyn-Lajeunesse M, Hunt LP, Heath PT, Finn A. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child 2012; 97: 487-490
58 Brotherton JML, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. Anaphylaxis following quadrivalent human papillomavirus vaccination. Can Med Ass J 2008; 179: 525-533